智通财经APP讯，卫信康(603676.SH)发布公告，近日，公司全资子公司内蒙古白医制药股份有限公司(简称“白医制药”)收到国家药品监督管理局(简称“国家药监局”)核准签发的琥珀酰明胶电解质醋酸钠注射液《药物临床试验批准通知书》。
公司全资子公司白医制药申报的琥珀酰明胶电解质醋酸钠注射液是以 B.Braun Melsungen AG 持证的 Succinylated Gelatin Electrolytes Injection 为参比制剂开发，本品作为溶解在等渗电解质平衡型溶液中的胶体血浆容量代用品，用于：1、相对或绝对的低血容量及休克的治疗。2、与晶体溶液联合用药作为灌注液的成分参与体外循环的过程(例如：心肺机)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.